BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1357 related articles for article (PubMed ID: 27255302)

  • 21. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).
    De Ruysscher D; Wanders R; Hendriks LE; van Baardwijk A; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
    J Thorac Oncol; 2018 Dec; 13(12):1958-1961. PubMed ID: 30253974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Ablative Radiation Therapy for Pulmonary Recurrence-Based Oligometastatic Non-Small Cell Lung Cancer: Survival and Prognostic Value of Regulatory T Cells.
    Liu C; Sun B; Hu X; Zhang Y; Wang Q; Yue J; Yu J
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1055-1064. PubMed ID: 31437470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
    Spaggiari L; Bertolaccini L; Facciolo F; Gallina FT; Rea F; Schiavon M; Margaritora S; Congedo MT; Lucchi M; Ceccarelli I; Alloisio M; Bottoni E; Negri G; Carretta A; Cardillo G; Ricciardi S; Ruffini E; Costardi L; Muriana G; Viggiano D; Rusca M; Ventura L; Marulli G; De Palma A; Rosso L; Mendogni P; Crisci R; De Vico A; Maniscalco P; Tamburini N; Puma F; Ceccarelli S; Voltolini L; Bongiolatti S; Morelli A; Londero F
    Lung Cancer; 2021 Apr; 154():29-35. PubMed ID: 33610120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: a follow-up study of 70 patients.
    Abrahams JM; Torchia M; Putt M; Kaiser LR; Judy KD
    J Neurosurg; 2001 Oct; 95(4):595-600. PubMed ID: 11596953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain Metastases of Non-Small Cell Lung Cancer: Prognostic Factors in Patients with Surgical Resection.
    Antuña AR; Vega MA; Sanchez CR; Fernandez VM
    J Neurol Surg A Cent Eur Neurosurg; 2018 Mar; 79(2):101-107. PubMed ID: 28586934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.
    Parikh RB; Cronin AM; Kozono DE; Oxnard GR; Mak RH; Jackman DM; Lo PC; Baldini EH; Johnson BE; Chen AB
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):880-7. PubMed ID: 24867533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome of node-negative oligometastatic non-small cell lung cancer.
    Sakai K; Takeda M; Hayashi H; Tanaka K; Okuda T; Kato A; Nishimura Y; Mitsudomi T; Koyama A; Nakagawa K
    Thorac Cancer; 2016 Nov; 7(6):670-675. PubMed ID: 27755813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer.
    Tamjid B; Phan P; John T; Mitchell P; Gan H
    Head Neck; 2017 Aug; 39(8):1544-1549. PubMed ID: 28593651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
    Mitchell KG; Farooqi A; Ludmir EB; Corsini EM; Zhang J; Sepesi B; Vaporciyan AA; Swisher SG; Heymach JV; Zhang J; Gomez DR; Antonoff MB
    Clin Lung Cancer; 2020 Jan; 21(1):37-46.e7. PubMed ID: 31447303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical treatment of primary lung cancer with synchronous brain metastases.
    Billing PS; Miller DL; Allen MS; Deschamps C; Trastek VF; Pairolero PC
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):548-53. PubMed ID: 11547308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Operation and Chemotherapy: Prognostic Factors for Lung Cancer With One Synchronous Metastasis.
    Toffart AC; Duruisseaux M; Brichon PY; Pirvu A; Villa J; Selek L; Guillem P; Dumas I; Ferrer L; Levra MG; Moro-Sibilot D
    Ann Thorac Surg; 2018 Mar; 105(3):957-965. PubMed ID: 29397931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
    Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
    Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
    Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
    BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
    Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
    J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients: Turkish Society for Radiation Oncology Group Study (TROD 10-003).
    Duru Birgi S; Akgun Z; Hurmuz P; Akyurek S; Kaytan Saglam E; Yilmaz MT; Bakirarar B; Cengiz M
    Am J Clin Oncol; 2022 Jan; 45(1):40-47. PubMed ID: 34857699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study.
    Arrieta O; Barrón F; Maldonado F; Cabrera L; Corona-Cruz JF; Blake M; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; García O; Arén O; De la Garza J
    Lung Cancer; 2019 Apr; 130():67-75. PubMed ID: 30885354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer.
    Johnson KK; Rosen JE; Salazar MC; Boffa DJ
    Ann Thorac Surg; 2016 Oct; 102(4):1166-71. PubMed ID: 27344278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.